GlassScriptPhysician profile
Roy Steven Paulson
NPI 1518901263
$20,409.90
in general payments reported to CMS, 2019-2025
22 companies · $10K in 2025
The $10K reported for 2025 was more than what 81% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,142 · 2020: $856 · 2021: $1,078 · 2022: $812 · 2023: $949 · 2024: $381 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,656 · Food and Beverage: $1,975 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,890.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,656.00 |
| Food and Beverage | $1,974.89 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,890.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $7,656.00 | 2025 | |
| Genentech USA, INC. | $6,402.03 | 2019-2022 | |
| Array Biopharma INC | $1,890.00 | 2025 | Braftovi |
| Aveo Pharmaceuticals, INC. | $900.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $884.42 | 2019-2025 | Imfinzi, Tagrisso, Calquence |
| Tersera Therapeutics LLC | $750.00 | 2020 | |
| Merck Sharp & Dohme LLC | $478.84 | 2022-2025 | |
| Mirati Therapeutics, INC. | $253.37 | 2023 | Krazati |
| Servier Pharmaceuticals LLC | $214.61 | 2023 | |
| Janssen Biotech, INC. | $169.04 | 2024 | Darzalex, Rybrevant, Erleada |
| Adc Therapeutics America, INC. | $149.49 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $145.15 | 2022 | |
| Genzyme Corporation | $110.72 | 2023-2024 | |
| Amgen INC. | $108.16 | 2022 | |
| Novartis Pharmaceuticals Corporation | $95.94 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adaptive Biotechnologies Corporation | $49.41 | 2025 | Clonoseq |
| Sun Pharmaceutical Industries INC. | $46.82 | 2019-2020 | |
| Abbvie INC. | $29.62 | 2025 | |
| Pharmacyclics LLC, An Abbvie Company | $24.93 | 2022 | |
| Tesaro, INC. | $21.24 | 2019 | |
| Advanced Accelerator Applications | $15.45 | 2019 | |
| F. Hoffmann-La Roche Ag | $14.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Paulson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.